Instil Bio
Dr. Matcham had 30 successful years at Celgene Corporation, joining in 1988 soon after the IPO when the company had 30 employees, and retiring in 2018 with the company soon to be valued at $74Billion in the acquisition by BMS. During his time at Celgene, he focused mainly on Biotech Research, Development and Manufacturing and held positions such as COO of Celgene Cellular Therapeutics, SVP of Biologics Development and Manufacturing, and SVP CAR T CMC & Technology Development. In these roles, he led internal technical development and clinical manufacturing and was extensively involved in external programs in Biologics and Cell Therapy development, including co-leading CAR T cell manufacturing in the collaboration with Juno, and representing Celgene on the Sutro Biopharma Board of Directors. Before coming to the USA, Dr. Matcham held academic positions in teaching and research at the University of Cambridge and obtained a PhD in Biochemistry at Cardiff University.
This person is not in the org chart
This person is not in any offices
Instil Bio
1 followers
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.